If youre unsure about any step or experience unexpected side effects, consult your healthcare provider right away
You can reference the EWGs Skin Deep database online or get the app (available for iPhone or Android)
Semaglutides CV event reduction indication already comes from the SELECT trial which supported its FDA approval and payor reimbursement Prior to its cardiovascular approval in March 2024, semaglutide was already approved for diabetes (Ozempic) and weight loss (Wegovy)
By enhancing your body's fundamental repair processes, reducing inflammation, boosting collagen, and protecting your cells, we are not just treating symptoms
doi: 10.1186/s12891-022-05396-5 Summary Keywords type 2 diabetes, osteoporosis, GLP-1 receptor agonists, electronic medical records, cohort study, bone metabolism, fracture risk Citation Chen M, Lyu Y, Zhao J, Han X, Huang T, Yang T and Zhou Y (2025) Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study
S2B and Fig